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Abstract
Background: Fundamental to definitively identifying neonates at risk of developing significant hyperbilirubinemia
is a better understanding of the genetic factors associated with early bilirubin rise. Previous genetic studies have
focused on the UGT1A1 gene, associating common variation in the coding or promoter regions with qualitative
assessments of bilirubin (i.e. significantly elevated or not). These studies have had conflicting results and limited
success. We chose to approach the problem by focusing on the quantitative (absolute) change in bilirubin levels
early in post-natal life. We apply this approach to the UGT1A1 gene - exploring the contribution of both rare and
common variants to early bilirubin changes.
Methods: We sequenced the exons, PBREM, 5’-, and 3’- regions of the UGT1A1 gene in 80 otherwise healthy term
neonates who had repeat bilirubin levels measured within the first five days of life.
Results: Three novel coding variants were observed, but there was no clear relationship between rare coding
variants and bilirubin rise. Adjusted linear regression models fit to evaluate the relationship between changing
bilirubin levels and common UGT1A1variants found that among 39 neonates whose bilirubin was resampled within
33 hours, individuals homozygous for the mutant allele of a 3’UTR SNP had significantly smaller changes in
bilirubin (P = 0.003) than individuals carrying the wild-type allele.
Conclusions: Collectively, rare UGT1A1 coding variants do not appear to play a prominent role in determining
early bilirubin levels; however common variants in the 3’ UTR of UGT1A1 may modulate the early bilirubin rise. A
quantitative approach to evaluating early bilirubin kinetics provides a more robust framework in which to better
understand the genetics of neonatal hyperbilirubinemia.
Background
Neonatal hyperbilirubinemia affects 60% of full-term
newborns and remains a significant cause of hospital re-
admission in the first week of life [1,2]. With most new-
borns being discharged from hospital at 48 hours of life
- a time when serum unconjugated bilirubin levels are
still rising - the American Academy of Pediatrics has
placed more emphasis on identifying infants at increased
risk of developing significant hyperbilirubinemia [3].
These infants require closer follow-up to stave off the
potentially devastating neurological effects of bilirubin
encephalopathy.
In practice, an otherwise healthy term newborn’sr i s k
for developing severe ‘physiological’ hyperbilirubinemia
is largely a function of their bilirubin level at discharge.
Bilirubin, when plotted on an hour-specific nomogram,
often directs the need for future evaluation [4-6].
Among those identified as being at high or high-inter-
mediate risk at discharge, however, only 8% will subse-
quently develop significant hyperbilirubinemia [6]. One
s t u d ye s t i m a t e dt h ep o s i t i v ep r e d i c t i v ev a l u eo ft h ed i s -
charge bilirubin at 48% [7], underscoring the difficulty
in predicting bilirubin rise during the first week of life.
Ideally, a simple combination of clinical and laboratory
information would definitively identify those infants
whose bilirubin levels are likely to rise substantially,
while minimizing the associated costs and anxiety to
those with lower risks. Fundamental to this goal is a
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early rise of bilirubin.
The production and degradation of bilirubin is multi-
factorial and complex, involving both maternal and new-
born factors as well as innate genetic factors (see [8]).
Recent data, however, suggests that assessing additional
maternal and neonatal factors beyond discharge biliru-
bin level and gestational age, does not significantly
improve the accuracy of risk stratification [6]. This
implies that innate or genetic factors may play an
important role in determining the rise of bilirubin in the
first week of life. The rate limiting enzyme in the hepa-
tic conjugation of bilirubin is UDP-glucoronosyl trans-
ferase A1 (UGT1A1)[9], the activity of which is
controlled by variants in the gene of the same name
(OMIM - 191740).
Common variants in UGT1A1 have long been thought
to influence the occurrence of severe physiological hyper-
bilirubinemia in neonates [10]; however, the multifactor-
ial nature of the disorder has made it difficult to decipher
this relationship. For example, a common missense
mutation at position 211 in exon one of UGT1A1 has
been consistently associated with significant and persis-
tent hyperbilirubinemia in neonates of East Asian ethni-
city [11-13], but is relatively rare in Caucasian or African
populations [14]. In the latter populations, the common
TA repeat motif in the 5-prime (5’) promoter region,
associated with the Gilbert syndrome phenotype in later
life [15], has been intensely scrutinized; possession of 7
or more TA repeats in combination with G-6-PD defi-
ciency has been associated with significant hyperbilirubi-
nemia in neonates [16,17]. A similar number of repeats
has also been reported in association with both an
increase in bilirubin over the first 48 hours of life [18]
and a slower return to baseline bilirubin levels [19].
Despite this, the precise role of UGT1A1 in exagger-
ated physiological hyperbilirubinemia remains equivocal;
subsequent studies have been unable to replicate many
of the above associations [20,21], while other potentially
associated regions such as the upstream Phenobarbital
response enhancer module (PBREM) [22], a regulator of
UGT1A1 activity, has scarcely been evaluated [23]. Most
recently, Watcho and colleagues [24] evaluated the role
of eleven common, previously described UGT1A1 var-
iants in a case-control study of severe hyperbilirubine-
mia (defined as having a peak bilirubin level > 95
th
percentile). They were unable to find statistically signifi-
cant differences in the frequency of any of the UGT1A1
variants between cases and controls; citing the ethnic
diversity of the sample groups as a possible confounder,
and conceding that a comparison of neonates with bilir-
ubin levels above the 95th percentile versus those with
levels below the 40th percentile may not be a robust
discriminator of genotypes related to hyperbilirubinemia.
Given this complexity, we considered whether a study
designed around the clinical conundrum of predicting
the change in bilirubin levels, rather than the absolute
occurrence of significant hyperbilirubinemia, might lead
to a better understanding of early bilirubin kinetics.
This approach can substantially improve the statistical
power of genetic studies [25], and is being used in the
current wave of genome-wide association studies [26].
Along with this, we also wished to interrogate new and
as yet untested variants within UGT1A1. To explore the
dynamics of this approach, we performed a pilot study
of quantitative changes in bilirubin designed to identify
potential susceptibility loci influencing early bilirubin
levels. We sequenced the UGT1A1 gene, including the
PBREM region, the 5’ and 3’ untranslated regions
(UTR’s), and all five exons, in a population of eighty
otherwise healthy term neonates who had repeated bilir-
ubin evaluations in the first 5 days of life.
Methods
Study Subjects
Study participants were chosen retrospectively from
among a cohort of neonates born at the Rochester
Methodist Hospital, Mayo Clinic in Olmsted County,
Minnesota. These neonates were all enrolled in a pre-
vious study of transcutaneous bilirubin estimation car-
ried out at our institution [27]. Briefly, this included 178
non-consecutive, near-term to term (gestational age
greater than 35 weeks), otherwise healthy newborns who
were thought to be clinically jaundiced prior to dis-
charge from the newborn nursery. The parents of all
participants consented to their newborn undergoing a
measurement of a transcutaneous bilirubin alongside the
usual serum bilirubin measurement. Each neonate’s
gestational age at birth, postnatal age at time of serum
bilirubin measurement, and mother’se t h n i c i t yw a s
recorded at the time of initial enrollment.
From this cohort, we obtained permission to review
the medical record in order to determine those indivi-
duals who, as a matter of clinical course, required a
serum bilirubin to be repeated within 120 hours of life.
Thus all included participants would have had serum
bilirubin measurements done prior to discharge and
again within the first five days of life. These serum mea-
surements were the only bilirubin measurements used
in the study. Any participant who had a medically signif-
icant intervention (including phototherapy) done prior
to their repeat serum bilirubin, as well as those with a
positive Coombs test (where one was done), gestational
age less than 36 completed weeks, or a birth weight less
than 2.5 kg, were excluded from further consideration.
For the remaining 80 participants, details of weight at
discharge from hospital, medical illnesses (including a
positive newborn screen), and timing of samples were
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not differ significantly in demographic make-up from
the original cohort. Clinical and laboratory variables at
the time of each serum bilirubin measurement are given
in Additional file 1: Supplemental Table s1.
The study design was approved by the Institutional
Review Board of the Mayo Clinic.
Gene sequencing
Newborn screening cards (dried blood spots - DBS) for
each individual, initially obtained through informed con-
sent, were randomly assigned a unique identifier linking
the collated clinical information to the respective blood
spot, but untraceable to clinical identifiers.
DNA was extracted from each DBS using the EZ1
BioRobot (QIAGEN
®). Direct DNA sequencing was per-
formed according to previously published methods [28].
The non-coding DNA sequences (introns) were not
sequenced due to their very large sizes. Mutation Sur-
veyor
® (SoftGenetics
®, LLC, State College, PA), was
used to identify polymorphic variants from the sequence
data. Identified polymorphisms were then confirmed or
rejected through concordance between two observers
(NH and JS).
Recorded variants were then matched to the public
SNP database where possible, using dbSNP build 129
(http://www.ncbi.nlm.nih.gov/projects/SNP/). One SNP
(rs11568318) of minor allele frequency (MAF) 0.02 was
found to be out of Hardy-Weinberg equilibrium (P <
0.01 by chi-squared) and was excluded from further
study.
Linkage disequilibrium mapping and haplotype
construction
For the purposes of linkage disequilibrium mapping and
haplotype construction, we chose to exclude variants
with MAF < 0.10 since such SNPs are unlikely to be
informative in a sample sizes such as ours. Pairwise esti-
mates of linkage disequilibrium using absolute values of
D’ were calculated and graphically displayed using the
MARKER software (http://www.gmap.net/marker). Hap-
lotypes were statistically inferred using the algorithm
found in PHASE version 2.1[29].
Statistical analyses
Separate linear regression models were fit to evaluate
the relationship between the change in bilirubin level
(mg/dl) (second assessment minus first assessment) and
demographic or genetic factors. Each model was
a d j u s t e df o ra g e( i nh o u r s )a tt h ef i r s tb i l i r u b i na s s e s s -
ment, the level of the first bilirubin assessment, and the
time interval (in hours) between the two assessments.
The relationships were summarized by reporting the
parameter estimates, with corresponding ninety-five
percent confidence intervals (95% CI), and p-values
from the adjusted linear regression models. All calcu-
lated p-values were two-sided and p-values less than
0.05 were considered statistically significant. Analyses
were performed using the SAS version 9.0 software
package (SAS Institute, Cary, NC).
Results
Demographic factors
We first sought to determine whether any of the demo-
graphic or clinical characteristics of the study cohort
had an influence on the rise of bilirubin with time using
our adjusted linear regression models (see methods).
Under this model, gestational age (per week of maturity)
showed a significant negative association with the
change in bilirubin (Parameter estimate [slope] = -0.60
[95% CI, -0.99 to -0.21]; P = 0.003), i.e. for each addi-
tional week of gestational age at birth, the mean change
in bilirubin between the two samples was 0.60 mg/dl
lower. Percent weight loss demonstrated a trend toward
a larger increase in bilirubin with greater degrees of
weight loss, but this did not reach statistical significance
(Parameter estimate (slope) = +0.17 (95% CI, -0.02 to
0.37); P = 0. 075). Factors common to the cohort, such
as breastfeeding and maternal Caucasian ethnicity, were
not significantly associated with change in bilirubin,
either before or after adjustment. The details of the clin-
ical factors evaluated are given in Table 1.
Genetic factors
A total of 26 UGT1A1 gene variants were identified in
t h ec o h o r t( T a b l e2 ) .A l lw e r es i n g l eb a s es u b s t i t u t i o n s
except the previously described TA insertion site [15].
Twelve variants were represented in the UGT1A1 allele
database [30].
Coding variants
Table 3a gives the molecular details of the identified
coding variants. Five individuals (6.3%, 95% CI 2.1%
-14.0%) were heterozygous at four loci in the first exon
of UGT1A1. Three of these variants had not been pre-
viously described (positions +449, +341 and +540) and
of these, two coded for non-synonymous (missense)
amino acid changes. Three variants were found in asso-
ciation with either a heterozygous (6/7) or mutant
homozygous (7/7) variation of the TA promoter repeat
motif.
Clinically, four of the five individuals with coding var-
iants had an initial bilirubin that placed them in the
h i g ho rh i g h - i n t e r m e d i a t er i s kz o n e( T a b l e3 b ) .D e s p i t e
this, only one of these individuals (MS003) had a rate of
rise that was outside the sample distribution for increas-
ing bilirubin, i.e. more than two standard deviations
above the mean per-hour increase (mean (SD), 0.09
(0.08) mg/dl/hr), and only two individuals eventually
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both individuals were born at 37 weeks gestation. We
also examined the four other individuals in the broader
cohort who had a rate of bilirubin rise (mg/dl/hour)
greater than two standard deviations; one had a rare sin-
gleton allele of uncertain significance in the 3’UTR
(+18162), otherwise there was no clear relationship
between possession of a rare variant (coding or non-
coding) and an increased rate of bilirubin rise, irrespec-
tive of TA repeat status.
Common non-coding variants
Using adjusted linear regression models (see methods),
we evaluated the effect of common (MAF > 10%; N = 9)
variants on the rise of bilirubin. In our initial modeling
we did not find any significant association between
either genotype or allele and the change in bilirubin.
Bilirubin levels change in a non-linear fashion over the
first five days of life, particularly over the last three days.
As we had only two sample points over the entire time
p e r i o d ,w es u r m i s e dt h a tt h e r em i g h tb em o r eu n c e r -
tainty in the trajectory of bilirubin levels between
sampling intervals that were more distant than those that
were closer together. For those sampling intervals that
were closer together, any change in bilirubin would
appear more linear, thus better approximating the statis-
tical model we were using. We found that the distribu-
tion of sampling intervals in the cohort was bimodal
(Additional file 2: Supplemental figure f1a) with median
33 hours, and that the change in bilirubin was more uni-
form (slope of zero) across the group sampled at shorter
intervals, as opposed to the group sampled at greater
intervals (Additional file 2: Supplemental figure f1b).
We thus performed a sub-group analysis in which we
focused on those individuals who had their bilirubin re-
sampled within 33 hours (N = 39). The first step in this
analysis was to graphically evaluate whether there was
any visual difference in the mean change in bilirubin
between subjects having different genotypes. This
approach suggested a lower mean change in bilirubin of
Table 1 Demographic variables
Variable Total (N = 80)
Gender
Female 41 (51.3%)
Male 39 (48.8%)
Ethnicity
Caucasian 68 (85%)
Asian 8 (10%)
Hispanic 3 (3.8%)
Black 1 (1.3%)
Feeding method
Breast 71 (88.8%)
Bottle 5 (6.3%)
Both 4 (5%)
Gestational age (wks)
Median 39.0
Interquartile range 37.7, 39.7
Range 36.4 - 41.4
Gestational age
36 to < 38 weeks 23 (28.8%)
≥ 38 weeks 57 (71.2%)
Coombs status
Negative 15 (18.7%)
Unknown 65 (81.3%)
Birth weight (kilograms)
Mean (SD) 3.4 (0.4)
Range 2.5 - 4.5
Percent weight loss at discharge
Mean (SD) 6.1 (2.6)
Range -1.3* - 13.1
* Negative percent weight loss represents weight gain.
Table 2 Sequence variants observed in UGT1A1
dbSNP no. * Allele/SNP
alias
Chr. pos. Major
allele
Minor
allele
MAF
rs11568318 *89 234330237 C A 0.02
rs4124874 *60 234330398 T G 0.40
rs11568319 *91 234330500 C G 0.01
rs11568317 *92 234330502 A G 0.01
- -3162 234330515 G C 0.01
rs10929302 *93 234330521 G A 0.29
- -136 234333537 C T 0.01
rs873478 *81 234333609 G C 0.01
rs34815109 *28/(TA) rpt 234333620 6 7 0.32
rs4148323 *6 234333883 G A 0.01
- +341 234334012 A G 0.01
- +449 234334120 C T 0.01
- +540 234334211 A G 0.01
rs6708136 - 234340306 C T 0.03
rs28946890 - 234341112 T C 0.01
rs34082659 - 234341148 C T 0.02
rs2302538 *66/*88 234341152 T C 0.10
rs12471326 - 234341197 T C 0.04
- +12724 234341376 A G 0.01
rs10929303 *76 234346155 C T 0.19
rs1042640 *78 234346283 C G 0.17
rs8330 *79 234346384 C G 0.21
- +17781 234346539 G T 0.01
rs17862880 - 234346795 C A 0.10
rs4148329 - 234346801 C T 0.65*
- +18162 234346815 A G 0.01
Chromosome position (Chr. pos.), dbSNP numbers, and minor allele are
referenced to dbSNP build 129. Where there was no previous description for
an allele, the approximate SNP position referenced from the ATG start site
was used. Approximate minor allele frequencies (MAF) are given in the final
column with alleles of MAF ≥ 0.10 used for subsequent association study
given in bold. * - dbSNP minor allele given as T; in our sample the C allele
was more common.
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rs4148329 versus persons with the wild-type homozy-
gous or heterozygous genotype (mean change in biliru-
bin = 1.52 vs. 3.01 or 2.84 mg/dl, for TT vs CT or CC -
Figure 1). When we applied our adjusted regression
model to this subgroup analysis, this difference was sig-
nificant under this recessive disease model (i.e. TT vs
CT or CC) (difference in adjusted mean change in bilir-
ubin = -1.78 (95% CI -2.90 to -0.66); P = 0.003), and
remained significant after accounting for the effects of
gestational age (P = 0.002). None of the other eight
SNPs showed any evidence of significant differences in
mean bilirubin level.
Linkage disequilibrium and haplotype analysis
In order to further appraise the contribution of common
variants to the rise of bilirubin, we also performed a
similar analysis using haplotypes inferred across the
UGT1A1 gene. We approached this by first determining
pair-wise linkage disequilibrium across the region. This
demonstrated two ‘blocks’ of strong linkage disequili-
b r i u m-d e f i n e da sD ’ between markers of 0.9 or more-
one in the 5’ region inclusive of markers between the
*60 allele and the TA repeat motif, and another in the
3’ region extending from the *76 allele to rs4148329
(Figure 2). We then constructed haplotypes (see Meth-
ods) in each of the two regions and repeated our multi-
variate analysis. For this analysis, haplotypes with
frequency less than 10% were not included. The mean
change in bilirubin was then analyzed among carriers of
each haplotype (without respect to hetero- or homo-
zygosity) versus non-carriers of the haplotype under test.
In the adjusted linear regression analysis using a simi-
lar sub-grouping (bilirubin re-sampled less than 33
hours later), none of the commonly observed haplotypes
were associated with a significant change in bilirubin
(Additional file 3: Supplemental Table s2).
Discussion
This is the first study of early bilirubin rise to sequence
the PBREM and 3 untranslated region in additional to
the exons and 5’ promoter of UGT1A1 in a Caucasian
sample. We found novel coding SNPs in exon one that
occurred independently of significant early increases in
bilirubin. We also found a SNP in the 3’ untranslated
region of the gene that, on subgroup analysis, showed
an inverse relationship with bilirubin rise; this was inde-
pendent of gestational age, which was also inversely
associated with greater rises in bilirubin. Most impor-
tantly, this study provides a unique framework in which
to further evaluate the role of UGT1A1 variants in early
bilirubin rise.
Any evaluation of neonatal hyperbilirubinemia, genetic
or otherwise, will necessarily include clinical parameters
usually evaluated in jaundiced neonates. In keeping with
t h ef a i r l yh o m o g e n o u se t h n i cd i s t r i b u t i o no fO l m s t e d
County, most mothers reported their ethnicity to be Cau-
casian. This reduces the impact of population stratification
inherent in the incidence and etiology of neonatal hyperbi-
lirubinemia, and accordingly, our major conclusions did
not change when we excluded those neonates with non-
Caucasian ethnicity (data nots h o w n ) .M o s tn e o n a t e si n
our cohort were also breastfed, reducing the likelihood
that observed differences in hyperbilirubinemia were the
Table 3 Observed UGT1A1 coding variants
3a
Individual Chr. pos. Exon Gene
pos.
AA pos. SNP
change
(TA) rpt Type
a original AA new AA
MS003 234334120 1A 449 150 C ® T 6/7 N/S Threonine Methionine
MS036 234333883 1A 211 71 G ® A 6/6 N/S Glycine Arginine
MS057 234333883 1A 211 71 G ® A 6/7 N/S Glycine Arginine
MS039 234334012 1A 341 114 A ® G 7/7 N/S Lysine Arginine
MS081 234334211 1A 540 180 A ® G 6/6 S Glutamic
Acid
Glutamic Acid
3b
Individual Maternal
ethnicity
GA % wt
loss
b
Feeding
method
Initial
bilirubin
Initial risk
zone
c
Repeat
bilirubin
Repeat risk
zone
c
Bilirubin increase
(mg/dl per hr)
Required
Phototherapy
MS003 Caucasian 37.0 6.4% Breast 10.2 LI 16.9 High 0.29 Yes
MS036 Asian 37.0 7.7% Breast 13.6 High 20.9 High 0.16 Yes
MS057 Asian 37.4 -0.4% Bottle 12.5 LI 15.0 HI 0.16 No
MS039 Caucasian 39.4 3.1% Bottle 11.3 HI 10.3 Low -0.02 No
MS081 Caucasian 39.9 4.9% Breast 12.2 HI 14.9 HI 0.10 No
Table 3a gives the molecular characteristics of the observed variables for each individual. Chromosome position (Chr. pos.), Gene position (Gene pos.) and amino
acid (AA) position (pos.) are given with reference to dbSNP build 129.
aN/S = non-synonymous substitution; S = synonymous substitution. Table 3b gives the
associated clinical characteristics for each individual.
bnegative percent weight loss (% wgt loss) is a gain of weight.
cnomogram based risk zones; LI = low
intermediate; HI = high intermediate.
Hanchard et al. BMC Medical Genetics 2011, 12:57
http://www.biomedcentral.com/1471-2350/12/57
Page 5 of 8result of differences in feeding preferences. We found
gestational age (per week of increased maturity) to be
inversely associated with an increase in bilirubin. This is
consistent with larger studies of clinical factors affecting
neonatal hyperbilirubinemia [6]. We also found a trend
toward a positive association between weight loss at dis-
charge (per 1% loss) and a greater rise in bilirubin, which
likely reflects the known effect of breastfeeding and
decreased volume intake in the initial days after birth.
Sequencing the UGT1A1 gene allowed us to evaluate
the collective effect of rare coding variants on early
bilirubin rise. The rare variation observed was limited to
exon one, consistent with the conserved nature of exons
2 to 5, which are common to all UGT1 genes; three of
the four coding SNPs observed have not, to the best of
our knowledge, been previously described. The variant
at position +449 encodes a non-synonymous amino acid
change from Threonine to Methionine. This is an unu-
sual substitution that results in a change from a hydro-
philic to a hydrophobic amino acid. Although the
individual with this change was in the low-intermediate
risk zone at the time of discharge, the subsequent rate
of rise of bilirubin over time was more than two stan-
dard deviations beyond the distribution of the cohort,
and resulted in subsequent re-admission for photother-
apy after repeat sampling. Despite this, there was no
definite relationship between possession of a heterozy-
gous coding SNP and hyperbilirubinemia. For instance,
the well-described *6 allele commonly found in persons
of East-Asian ethnicity, was found in conjunction with
the supposedly protective wild-type TA repeat (6/6), and
this individual was not only at high risk at the time of
discharge, but had a sharp increase in bilirubin and ulti-
mately required phototherapy; conversely another indivi-
dual with the *6 allele was heterozygous at the TA
repeat (6/7), was low-intermediate risk at birth, and did
not require any intervention. This illustrates the imper-
fect relationship between coding variants and early bilir-
ubin levels and underscores the complex multifactorial
nature of the disease.
When we focused on the common variants observed
in the cohort, we found that among neonates whose
bilirubin was re-sampled at less than 33 hours, homozy-
gotes for the mutant ‘T’ allele of the rs4148329 SNP had
a significantly smaller (mean) change in bilirubin than
*
*P < 0.003
Figure 1 Change in bilirubin level (between 1
st and 2
nd
bilirubin measurements, mg/dl) by genotype for two UGT1A1
SNPs among neonates who had a repeat bilirubin measured
within 33 hours. Figure 1a illustrates the association with SNP
rs4148329 - a smaller change is observed for neonates who were
homozygous for the mutant allele versus those with wild-type
genotypes. This was significant at the P < 0.003 level. A non-
significant association with a SNP of comparable minor allele
frequency is given in the lower figure (1b) for comparative
purposes. In each figure the change in bilirubin for each neonate is
given as a diamond; the green lines are the mean values for each
genotype and the blue bars show the standard error of the mean.
Figure 2 Pair-wise linkage disequilibrium (LD) across UGT1A1
using common markers (minor allele frequency ≥ 10%). Black
boxes indicate pair-wise D’ values ≥ 0.9; dark gray boxes indicate D’
values > 0.7 but < 0.9; light gray boxes indicate D’ values between
0.5 and 0.7; D’ values < 0.5 are indicated by a cross. Two ‘blocks’ of
strong LD (D’ ≥ 0.9) are seen at the 5’ and 3’ ends.
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Our evaluation of the 3’-UTR is novel among studies of
neonatal hyperbilirubinemia, thus a putative role for
rs4148329 is unclear; it encodes a predicted mRNA reg-
ulatory binding site in the 3’ -UTR for which there is no
current functional data and there are no previous asso-
ciations establishing it’s role in hyperbilirubinemia.
Recent work [31], however, suggests that the 3’-UTR is
more complex than hitherto thought, including the
description of alternate splice variants of the last exon
of UGT1A1 that encode widely-distributed isoforms of
UGT1A1 that are functionally divergent. The 3’-UTR of
UGT1A1 thus represents an interesting and emerging
area that warrants further investigation. In the absence
of such studies, however, any definitive conclusion
about the role of rs4148329 in the early rise of bilirubin
remains speculative.
The retrospective sampling that shaped the clinical
distribution of the cohort and the sample size employed
in the study meant that our pilot protocol was primarily
geared toward looking at the collective role of rare,
rather than common, UGT1A1 variants. We did not
find strong evidence for the role of common 5’-promo-
ter variants, including the Gilbert syndrome (TA) repeat
motif, in early bilirubin rise in this population. This may
b er e f l e c t i v eo ft h es t u d yp o p u l a t i o n ,t h eq u a n t i t a t i v e
approach taken, or the modest sample size employed,
which limited our ability to definitively identify common
variants with relatively small effect sizes of the kind
expected for the Gilbert genotype. The linkage disequili-
brium pattern observed also underscores the complexity
of studying genetic susceptibility to neonatal hyperbiliru-
binemia; although we limited our appraisal to common
population variants, we still observed strong LD between
markers in the 5’ and 3’ regions respectively. This strong
LD suggests that refining association signals found in
either region will be challenging, and may explain the
difficulty in replicating previous associations across dif-
fering populations with differing local LD patterns.
Our quantitative approach to hyperbilirubinemia is
somewhat unique, and despite the exploratory nature of
this pilot study, it provides a framework for a larger and
more comprehensive evaluation of susceptibility genes
in the early rise of bilirubin. The quantitative trait
approach allowed us to evaluate a broad range of
changes in bilirubin as opposed to the qualitative out-
come of ‘significant hyperbilirubinemia’ that has been
the focus of previous studies. For instance, our SNP
association suggests that there may be variants that
attenuate the early rise in bilirubin; this may not be
readily apparent with a qualitative approach in which
such observations are unlikely to be represented. Our
study also suggests that, ideally, individuals should be
sampled at regular intervals over the first few days of
life. This would circumvent the non-linearity of bilirubin
rise and facilitate the use of a more robust statistical
model to better exploit the inherent power advantages
of a quantitative approach. Finally, it is worth noting
that a quantitative approach could be undertaken in
conjunction with a genome-wide SNP scan; such gen-
ome-wide association studies have been utilized to iden-
tify genetic determinants of bilirubin levels in adults
[32,33], and could ultimately lead to a better under-
standing of the genetic factors controlling the early neo-
natal bilirubin rise.
Conclusions
Our results suggest that rare coding variants do not col-
lectively play a significant role in the early rise of biliru-
bin, while common variants in the hitherto unevaluated
3’UTR may modulate early bilirubin rise in this popula-
tion. A quantitative approach to the evaluation of early
bilirubin changes may provide a more robust statistical
framework in which to determine genetic variants that
both augment and attenuate physiological ex-utero
changes in bilirubin.
Additional material
Additional file 1: Sampling time characteristics. Summary of clinical
and bilirubin characteristics at each sampling time.
Additional file 2: Bilirubin by sampling interval. Bilirubin levels and
change in bilirubin for individuals sampled less than and more than 33
hours post first sample.
Additional file 3: Common-haplotype associations by region.
Haplotype frequencies, parameter estimates, and P-values for common
haplotypes inferred in the proximal (5’) and distal (3’) portions of
UGT1A1.
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